| Added by | standudu |
|---|---|
| Group name | EquipeCTCS |
| Item Type | Journal Article |
| Title | Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers |
| Creator | Viala et al. |
| Author | Marie Viala |
| Author | Marie Alexandre |
| Author | Simon Thezenas |
| Author | Pierre-Jean Lamy |
| Author | Aurélie Maran-Gonzalez |
| Author | Marian Gutowski |
| Author | Pierre-Emmanuel Colombo |
| Author | Gilles Romieu |
| Author | William Jacot |
| Abstract | PURPOSE: Intermediate-risk early breast cancer (EBC) is a heterogeneous group in which adjuvant chemotherapy decision proves to be difficult. Clinical and pathological criteria are sometimes insufficient to determine the best therapeutic options, and validated biomarkers such as uPA/PAI-1, are needed to contribute to the decision-making. The objective of this study was to evaluate the clinical outcome of an unselected ER+/HER2- pN0 EBC cohort of patients in whom the routine clinical decision process included a prospective uPA/PAI-1 determination. METHOD: This monocentric retrospective study included 520 patients who underwent curative surgery in our institute between 2006 and 2011. Adjuvant therapeutic strategy was decided based on clinical-pathological data, altogether with a routine prospective determination of uPA/PAI-1 tumor levels using fresh, extemporaneously sampled tissue. We evaluated the correlation between uPA/PAI-1 levels, clinical-pathological variables, and the patient's outcome (relapse-free survival, RFS, and overall survival, OS). RESULT: Median follow-up was 5.4 years. The 5- and 10-year RFS rates were ,respectively, 95 and 89%, and the five-year OS rate was 96.3%. Forty percent of tumors had low uPA/PAI-1 levels. Seventy-five percent of patients with low uPA/PAI-1 levels did not receive chemotherapy, when 25% did. Sixty percent of patients with high uPA and/or PAI-1 levels received chemotherapy, while 40% did not. No statistical significant correlation was found between the uPA/PAI-1 levels and RFS or OS. CONCLUSION: The personalization of the patients' treatment using uPA/PAI-1 tumor levels allows the reversion of the well-known poor prognostic impact of high uPA/PAI-1 levels and strongly supports the use of this biomarker in clinical practice. |
| Publication | Breast Cancer Research and Treatment |
| Volume | 165 |
| Issue | 3 |
| Pages | 611-621 |
| Date | Oct 2017 |
| Journal Abbr | Breast Cancer Res. Treat. |
| Language | eng |
| DOI | 10.1007/s10549-017-4373-7 |
| ISSN | 1573-7217 |
| Library Catalog | PubMed |
| Extra | PMID: 28685212 |
| Tags | Adjuvant chemotherapy, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Breast Neoplasms, Chemotherapy, Adjuvant, clinic, Clinical Decision-Making, Female, Humans, Middle Aged, Neoplasm Grading, Neoplasm Staging, Plasminogen Activator Inhibitor 1, Prognosis, Receptor, ErbB-2, Receptors, Estrogen, Recurrence, Survival Analysis, Tailoring, Treatment Outcome, uPA/PAI-1, Urokinase-Type Plasminogen Activator |
| Date Added | 2018/11/14 - 15:24:24 |
| Date Modified | 2019/05/14 - 18:53:02 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
